Top-News
Gesundheitswesen: Anbieter u. Dienstleister USA

Compass Pathways News

Aktie
WKN:  A2QCDR ISIN:  US20451W1018 US-Symbol:  CMPS
7,90 €
-0,15 €
-1,86%
09.05.24 14:35:53
Handeln Depot/Watchlist
Aktienanzahl *
61,90 Mio.
Marktkapitalisierung *
489,49 Mio. €
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 27.11.2023

Compass Pathways News

08.05.24 - GlobeNewswire
Compass Pathways Announces First Quarter 2024 Financial Results and Business Highlights
COMP360 phase 3 pivotal program in treatment-​resistant depression (TRD) on track for top-line COMP005 trial data in fourth quarter 2024, COMP006 trial top-line data expected mid-...
08.05.24 - GlobeNewswire
Compass Pathways announces durable improvement in symptoms through 12 weeks in open-label phase 2 study of COMP360 psilocybin in post-traumatic stress disorder
Study met primary safety endpoint; administration was well tolerated, with no serious adverse events observed Early and clinically meaningful improvement from baseline in mean ...
02.05.24 - GlobeNewswire
Compass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational COMP360 psilocybin treatment
LONDON, May 02, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to ...
29.04.24 - GlobeNewswire
Compass Pathways and Journey Clinical establish research collaboration agreement to inform the training of healthcare providers and delivery model for COMP360 psilocybin treatment, if approved for treatment-resistant depression
LONDON, April 29, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to ...
28.03.24 - GlobeNewswire
Compass Pathways Board Chair and Co-Founder George Goldsmith and Co-Founder Ekaterina Malievskaia Step Down from Board of Directors
David Norton Assumes Role of Interim Board Chair while the Company Runs a Global Search for a New Chair
29.02.24 - GlobeNewswire
Compass Pathways Announces Fourth Quarter 2023 Financial Results and Business Highlights 
LONDON, Feb. 29, 2024 (GLOBE NEWSWIRE) --
16.01.24 - GlobeNewswire
Compass Pathways enters into research collaboration agreement with Hackensack Meridian Health to develop optimal clinical model for investigational COMP360 psilocybin treatment, if FDA-approved
LONDON, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to ...
05.01.24 - GlobeNewswire
Compass Pathways and Greenbrook TMS enter into three-year research collaboration agreement
Three-​year research collaboration will investigate the development of scalable, commercial delivery models for COMP360 psilocybin treatment, if FDA-​approved
19.12.23 - GlobeNewswire
Compass Pathways announces investigational COMP360 psilocybin treatment was well-tolerated in phase 2 study of post-traumatic stress disorder
Initial safety findings at 24 hours post dosing were consistent with studies of COMP360 in other psychiatric conditions
07.12.23 - GlobeNewswire
Compass Pathways appoints Teri Loxam as Chief Financial Officer
LONDON, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to ...
06.12.23 - GlobeNewswire
Study results of psilocybin treatment in bipolar II depression published in JAMA Psychiatry
Believed to be first ever psilocybin clinical trial for treatment of bipolar II depression
15.11.23 - GlobeNewswire
Compass Pathways initiates UK component of global phase 3 study of psilocybin treatment in treatment-resistant depression and launches new research center
UK sites to participate in part of pivotal phase 3 program following Medicines and Healthcare Regulatory Agency approval of study Research will take place in the UK, including at ...
02.11.23 - GlobeNewswire
COMPASS Pathways Announces Third Quarter 2023 Financial Results and Business Highlights
Highlights: COMP360 Phase 3 pivotal program ongoing with expanding European clinical sites Secured up to $285 million private placement financing with $125 million upfront ...
26.10.23 - GlobeNewswire
COMPASS Pathways announces CFO transition
LONDON, Oct. 26, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS” or the “company”), a biotechnology company dedicated to accelerating patient ...
18.09.23 - GlobeNewswire
COMPASS Pathways appoints Daphne Karydas to its Board of Directors
LONDON, Sept. 18, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a biotechnology company dedicated to accelerating patient access to ...
06.09.23 - GlobeNewswire
COMPASS Pathways announces publication of first study evaluating potential of AI model to predict outcomes of COMP360 psilocybin treatment in treatment-resistant depression
LONDON, Sept. 06, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a biotechnology company dedicated to accelerating patient access to ...
16.08.23 - GlobeNewswire
COMPASS Pathways Announces Up to $285 Million Private Placement Financing Joined by Leading Healthcare Investors
Transaction led by healthcare specialist investors, TCGX and Aisling Capital $125 million financing upfront with up to an additional $160 million tied to exercise of warrants Net ...
03.08.23 - GlobeNewswire
COMPASS Pathways Announces Second Quarter 2023 Financial Results and Business Highlights  
LONDON, Aug. 03, 2023 (GLOBE NEWSWIRE) --
25.07.23 - GlobeNewswire
First clinical study results of psilocybin treatment in anorexia nervosa published in Nature Medicine
COMP360 psilocybin treatment shows potential in exploratory open-​label investigator-​initiated study in anorexia nervosa
17.07.23 - GlobeNewswire
COMPASS Pathways announces publication of positive data from treatment-resistant depression phase 2 clinical trial of COMP360 psilocybin alongside antidepressants in Nature journal, Neuropsychopharmacology
Results of COMPASS Pathways’ open-​label study of COMP360 psilocybin treatment, alongside SSRI antidepressants, suggest that SSRIs do not interfere with the potential ...

Newssuche

Videos

newspaper
07.05.24 +17,87%
Technical Trading: DAX Long kurzfristig
DAX Long Typ: Turbo Open End WKN: NG8K9X Hebel: 26 Laufzeit: OpenEnd Einstieg: Market ... Mehr »